Ranbaxy Laboratories’ arm launches authorized generic of Evoxac in US

09 Oct 2012 Evaluate

Ranbaxy Laboratories’ (RLL) wholly owned subsidiary - Ranbaxy Pharmaceuticals Inc (RPI) has launched the authorized generic cevimeline hydrochloride 30 mg capsules in the US market, under an agreement with Daiichi Sankyo, Inc.

Cevimeline hydrochloride is indicated for the treatment of symptoms of dry mouth associated with Sjogren’s syndrome, an autoimmune disorder affecting the moisture-producing glands, and is presently distributed by Daiichi Sankyo, Inc. under the brand name Evoxac. Evoxac generated total annualized sales of $62.4 million in the US (IMS - MAT June 2012).

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories, India’s largest pharmaceutical company. The company is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×